Anteris Technologies Global Corp. priced its initial public offering at $6.00 a share, offering 14,800,000 shares of common Stock, to list on the Nasdaq Global Market under the symbol AVR. It filed a Form S-1 registration statement for an initial public offering on November 22, 2024. As of November 7, 2026, its final prospectus is on file (Form 424B4, December 13, 2024).
Sell to companies like Anteris Technologies Global Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Anteris Technologies Global Corp. filed a Form S-1 registration statement for an initial public offering on 2024-11-22. It has amended it 1 time. It filed its final prospectus on 2024-12-13, at a public offering price of $6.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Anteris Technologies Global Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.7% of the class | 5%+ stakes | Source |
| September 17, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 8, 2026 | Leadership change: Brent Moen appointed, Chief Financial Officer | — | Leadership changes | Source |
| September 3, 2026 | Stake report, Schedule 13G/A, by L1 Capital Pty Ltd | 11.64% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 4.08% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by L1 Capital Pty Ltd | 13.46% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 7.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 6.28% of the class | 5%+ stakes | Source |
| May 13, 2026 | Leadership change: Susan Knight appointed, and 1 more | — | Leadership changes | Source |
| May 4, 2026 | Stake report, Schedule 13G/A, by Sio Capital Management, LLC | 5.54% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.01% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 7.52% of the class | 5%+ stakes | Source |
Check before you invest in Anteris Technologies Global Corp.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Anteris Technologies Global Corp. and the records around it.
Anteris Technologies Global Corp. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
- Form D filing Nov 2025
- Who owns it
Companies that share a holder
- Medtronic plc also filed stake reports on 2 other companies: Orchestra BioMed Holdings, Inc. (Feb 2026)
- L1 Capital Pty Ltd also filed stake reports on 4 other companies: Eldorado Gold Corp (May 2026)
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
Watch Anteris Technologies Global Corp.
Get an email when Anteris Technologies Global Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Anteris Technologies Global Corp.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Anteris Technologies Global Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Anteris Technologies Global Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 22 records.
What the filings say
Listing
Our Common Stock is listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “AVR.” Our CDIs trade on the Australian Securities Exchange (the “ASX”) under the symbol “AVR.” On November 25, 2025, the closing price for our Common Stock on Nasdaq was $3.85 per share.From the S-1 filed 2025-11-26
Shares offered
We are offering 14,800,000 shares of our Common Stock to be sold in this offering at an initial public offering price of $6.00 per share.From the 424B4 filed 2024-12-13
Offering price
We are offering 14,800,000 shares of our Common Stock to be sold in this offering at an initial public offering price of $6.00 per share.From the 424B4 filed 2024-12-13
Use of proceeds
Unless we inform you otherwise in a prospectus supplement or free writing prospectus, we expect to use the net proceeds from the exercise of such Warrants primarily for the ongoing development of our DurAVR ® THV system, the preparation and enrollment of the PARADIGM Trial of DurAVR ® THV system for treating severe aortic stenosis, and ongoing R&D for v2vmedtech, with the remaining for working capital and other general corporate purposes determined from time to time.From the S-1 filed 2025-11-26
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-11-22 | Registration statement filed | S-1 |
| 2024-12-09 | Registration statement amended | S-1/A |
| 2024-12-13 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-11-26 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for Anteris Technologies Global Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.